Compare BigBearai Holdings Inc (BBAI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Merck & Co., Inc. — how do they compare? BigBearai Holdings Inc trades at $3.27 (market cap $1.60B), while Merck & Co., Inc. trades at $133.55 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 201.1× BigBearai Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | MRK | |
|---|---|---|
Market Cap | $1.60B | $321.77B |
Sector | Technology | Health |
52-Week High | $8.91 | $131.84 |
52-Week Low | $2.61 | $77.60 |
Enterprise Value | $1.30B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.26, up 0.93% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations, continuing negative profitability trends. Recent news highlights defense contract wins and generative AI platform expansion, while analyst consensus remains cautious with 75% hold ratings.
The outlook remains challenging with persistent losses and negative cash flow projections for 2026. Investment opportunity lies in defense AI specialization and backlog growth, but risks include execution challenges, high valuation multiples, and dependence on government contracts. The stock requires careful monitoring of profitability improvements.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
